Mitsuo Takahashi1}, Ryoichi Yuasa2), Terukuni Imai3), Hisao Tachibana4), Shiro Yorifuji5), Yusaku Nakamura1^and Nobuya Ogawa6T o confirm the clinical utility of selegiline (L-deprenyl), a selective inhibitor of monoamine oxidase B, as an anti-Parkinson's disease (PD) agent, the first Japanese multi-center, double-blind comparative study of this drug was conducted. The subjects were patients whohad responded poorly or suffered with other problems related to L-dopa treatment. A total of 112 patients in two groups, one given selegiline at a dose of7.5 mg/day (Group D, n=60) and another given a placebo (Group P, n=52), were compared over an 8-week treatment period. The percentage patients showing "moderate improvement" or better was 34.5% in Group D, while that in Group P was ll.5 % (P<0.01). In the assessment of overall safety, 66.7% in Group D showed no adverse reactions, which was not significantly different from the result of 78.9% for Group P. (Internal Medicine 33: 517-524, 1994) 
Introduction
The motor dysfunctions in Parkinson's disease (PD) are related to a deficiency in striatal dopamine resulting from the progressive degeneration of the dopamine-producing neurons of the substantia nigra. Therapy with L-dopa satisfactorily compensates for this deficiency, while the remaining neurons are still able to stimulate the dopamine receptors. However, due to the progression of this neural degeneration and as a consequence of massive, long-term L-dopa therapy, difficult problems may appear, such as a decrease of the efficacy of L-dopa, daily fluctuations in disability, frozen gait, dyskinesia and mental syndromes ( 1-4).
Oneapproach to treating these patients is to enhance the effects of striatal dopamineby using a selective monoamine oxidase B (MAO-B)inhibitor, such as selegiline (L-deprenyl) (5, 6) . Selegiline has been successfully used internationally in combination with L-dopa in the treatment of PD patients (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) . Selegiline is thought to be a very important drug for PD patients not only because of the enhancementof the striatal dopamine activity, but also the possibility of retarding disease progression (24-28).
In Japan, selegiline has been available for trial use since 1988. We have previously performed a phase-II open trial of selegiline with PD patients in the Kinki region of Japan (29). In that study selegiline was considered to be effective and safe at a daily dose of7.5 mg forpatients with PD who are being treated with L-dopa. Kondoet al (30) have also performed a phase-II open trial of this drug in the Kanto area of Japan. Their result with respect to the rate of "moderate improvement" or better was nearly the same as that of our previous study, 26.6%vs. 27.0%, respectively. Based on the results of our preceding trial, we performed a double-blind parallel-comparison multi-center study to objectively evaluate the utility of selegiline with Ldopa in the therapy of PD.
Materials and Methods
This study was conducted with the cooperation of 2 1 neurological departments of institutions in the Kinki region and with the permission of all involved institutional Review Boards. The subjects were patients with proven PD (excluding juvenile PD) receiving therapy with a combined agent ofL-dopa and dopamine decarboxylase inhibitor (DCI), and having a poor response or other problems related to L-dopa therapy. The inclusion criterion for Hoehnand Yahr stage was II, III, or IV, and only patients aged between 40 and 75 years were included. The patients selected were provided with information regarding the following points of the study before consenting to voluntarily participate : purpose and methods of study, expected efficacy and possible risks, possibility of any alternative therapy and information thereon, withdrawal is permitted at any time even after consent has been given, other necessary information with respect to patients' rights. The informed consent was obtained in written form whenever possible. Biochemical tests: GOT, GPT, ALP, LDH, y-GTP, BUN, creatinine, uric acid, total bilirubin, total protein, total cholesterol, CK, Na, K and Cl. Urinalysis: protein, glucose, occult blood and urobilinogen. Physiological tests: blood pressure (every 2 weeks, seated) and ECG. Investigators madeevaluations for the following parameters immediatelyafter completion of treatment or at the time of withdrawal. Global improvementat the completion of treatment was evaluated using the following scale: marked improvement, moderate improvement, slight improvement, no change, worsening and uncertain. Adverse reactions which appeared during the study and abnormal laboratory findings at the completion of treatment were comprehensively evaluated as to overall safety, and evaluation was made according to the following scale: safe, probably safe, possibly safe, unsafe, and safety uncertain. Froma comprehensiveconsideration of the global improvement and overall safety, the utility of the test drug was evaluated using the following scale: extremely useful, useful, fairly useful, not useful, harmful and utility uncertain. For comparison of the data between the test drug and control drug groups, the %2 test, Fisher' s direct probability test, the Mann-WhitneyU-test, or the t-test was applied as appropriate.
Results

Subjects
A total of 120 patients participated. Sixty-three were allocated to the selegiline + L-dopa group (Group D) and 57 to the placebo + L-dopa group (Group P). There were 60 patients who could be evaluated in Group D and 52 in Group P (8 subjects were excluded from the statistical analysis). Of the 1 12 patients who could be evaluated, 7 in Group D and 5 in Group P were discontinuation/dropout cases, and 2 of these 1 2 were excluded from the efficacy evaluation because the treatment duration was insufficient. Thus, overall improvementwasevaluated in a total of 1 10 patients (58 in Group D and 52 in Group P), and overall safety and utility were evaluated in 1 12 patients (60 in Group D and 52 in Group P). Of the 8 patients excluded from the data analysis, 3 had no baseline treatment with L-dopa, 1 had severe renal dysfunction, 1 case involved a substantially incomplete report, 2 patients received a drug with the wrong patient number, and 1 did not appear at the hospital for follow-up.
The main clinical profiles of the patients are shown in Fig. 1 . Sex ratio, family history, complications, past history, and treatment with other antiparkinsonian drugs were also not significantly different between the two groups. Meandoses of L-dopa with decarboxylase inhibitor at the starting point were 433.8+185.3 mg per day in Group D and 347.1+139.8 mg per day in Group P, and the difference in mean doses between both groups was significant (P=0.014). The assessment revealed no significant difference between the two groups in any of the parameters except the dose of L-dopa.
Global improvement
The evaluation results for global improvementare given in Table 1 . Statistical analysis showed that the improvement rate was significantly higher in Group D than in Group P (P<0.001 , U-test). A large difference was found between the two groups in the rate of "moderate" or better improvement (20/5 8 patients, 34 .5% vs. 6/52 patients, 1 1.5%), and this difference was statistically significant (P<0.01 , %2 test and Fisher' s test). We studied the influence of the dose difference of L-dopa on global improvement using the Mantel-Haenszel procedure, and a significant difference (P=0.007) between the two groups was also found after this correction. It was determined that the L-dopa dose did not influence the assessment.
Overall safety
The results of the overall safety evaluation are shown in Table 2 . The evaluation of "safe" was given for 40/60 patients of Group D (66.7%) and for 41/52 patients of Group P (78.9%). 1}Group selegiline (L-deprenyl), 2)Group placebo. Nostatistically significant difference was shownusing the litest. The rates for "safe" and those for evaluation ratings of less than "safe" were compared separately; no significant difference was shown using either the %2test or Fisher's test in both comparisons.
Utility
The results of the utility evaluation are shown in Table 3 In cases with improvement of the wearing-off phenomenon, Group D showed improvementin manyother symptoms; Group P patients, however, showed improvement in only a few symptoms other than the wearing-off phenomenon. Figure 3 shows the changes in the severity scores of someof the neurological and specific symptoms exhibited during the 8- adverse reactions were mild. Adverse reactions were cited as reasons for discontinuation of treatment or dropping out for 6/ 7 patients in Group D and for 3/5 patients in Group P, although the symptomsweremild or moderate in all cases. These adverse reaction symptoms disappeared or were palliated rapidly after withdrawal of selegiline treatment.
The number of patients with changes in laboratory test results (from normal to abnormal) in Group D were 4 patients with changes in LDHand 2 each with changes in RBCand hemoglobin. Except for 1 patient with a mild increase in the CK level (which was considered a side effect), no clinically significant abnormalities were noted in the laboratory findings. No significant changes were noted in the blood pressure and pulse rate data in both groups.
Discussion
The result in the present study for the rate of "moderate improvement" or better for Group D was nearly the same as that in ourprevious phase-II open study; 34.5% vs. 3 1.0% (dose: 7.5 mg/day), respectively (29). Also, compared with the results in Liebermanet al's summary(31) of 13 studies on the effects of deprenyl on 1070 PD patients from 1977-1986, the present result with respect to the rate of "slight improvement" or better for Group D was similar to their reported average improvement rate; 75.9% vs. 73.0%, respectively. The stratified comparison of the rates for moderate or better improvementdemonstrated that the rates in Group D were significantly higher for all the subgroups; in particular, the rate was notably high (40% or higher) for the 50-59 age subgroup, the duration-of-disease subgroup of 5-10 years, and the subgroup for Hoehn and Yahr stage III. It is considered that these patients were not in the markedly advanced stage and retained relatively intact endogenous dopaminestores. It was also revealed by Yahr et al (14) and Csanda and Tarczy (20) Regarding the symptom-specific efficacy of selegiline, the improvement rate in Group D was higher than that in Group P for almost all symptoms. Amongthem, tremor, frozen gait, finger tapping and rigidity were revealed to show a high rate of improvement, decreasing in that order. This present result showed nearly the same tendency as those in previous phase-II studies of this agent by the present authors (29) and Kondo et al (30) . Rinne ( 15) also pointed out that a tremor shows the highest rate of improvementof neurological symptomsafter the combination of selegiline with L-dopa. Manyclinical studies of selegiline demonstrated that the combination of selegiline with L-dopa is effective for the wearing-off (up-down) phenomenon (6- 23, 28, 3 1) . The present study also showed that the improvement rate of this symptom was higher in Group D than in Group P. Although, there was no significant difference in the improvement rate between GroupD and Group P, this symptomwas significantly improved in Group D at week 8, and infrequently associated with improvements in other symptomsin Group P.
The latter result was thought to be related to the placebo effect.
In conclusion, the present study confirmed that the combination of selegiline with L-dopa may significantly improve various neurological symptoms and the wearing-off phenomenon. These effects of selegiline are thought to depend on the increase in striatal dopamine activity mainly by inhibiting MAO-Bin the mitochondria of the nigral dopaminergic neurons and by blocking the re-uptake of extraneural dopamine (5, 32). Although much controversy remains (10, 12) , selegiline is also thought to exert some action leading to enhanced noradrenaline effects (32, 33), which might be effective in improving frozen gait symptoms (34).
The rate of occurrence of adverse reactions was higher in Group D (36.7%) than in Group P (25.0%), but no significant difference was found in the number of patients with adverse reactions between the two groups. All symptoms of adverse reactions were palliated or disappeared after withdrawal or completion of treatment. It was speculated that these adverse reactions mayaccount for the excessive increase in the cerebral DAlevel due to selegiline combination therapy (13, 28, 3 1) . To confirm this point, an investigation should be performed to examine the effect of a decrease in the dose of L-dopa. Furthermore, in the present study, since selegiline was administered over a short term (8 weeks) , and the dose of L-dopa was decreased in a total of only 4 patients, it appears that further investigations are necessary to clarify this point. Based on a comprehensive review of safety, it was concluded that selegiline is a very safe agent in comparison with the reported safety profiles of other antiparkinsonian drugs (34-37).
